Soleno Therapeutics to Participate in the BIO CEO & Investor Conference
Rhea-AI Summary
Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company, announced its CEO Anish Bhatnagar will present a corporate overview at the BIO CEO & Investor Conference on February 15, 2022, at 2:15 PM Eastern Time. The company focuses on developing novel therapeutics for rare diseases. Its lead candidate, DCCR extended-release tablets, is in Phase 3 clinical development for treating Prader-Willi Syndrome (PWS). For more information, visit www.soleno.life.
Positive
- None.
Negative
- None.
Insights
Analyzing...
REDWOOD CITY, Calif., Feb. 08, 2022 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that Anish Bhatnagar, M.D., Chief Executive Officer, will present a corporate overview at the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:15 PM Eastern Time.
About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR extended-release tablets, a once-daily oral tablet for the treatment of Prader-Willi Syndrome (PWS), is currently being evaluated in a Phase 3 clinical development program. For more information, please visit www.soleno.life.
Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
FAQ
What is the date and time of Soleno Therapeutics' presentation at the BIO CEO & Investor Conference?
Who will represent Soleno Therapeutics at the BIO CEO & Investor Conference?
What is the focus of Soleno Therapeutics?
What is DCCR and for which condition is it being developed?
Where can I find more information about Soleno Therapeutics?
